+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Specialty Generics Market by Product Type, Drug Delivery System, Molecule Type, Disease Indication, Distribution Channel - Global Forecast to 2030- Product Image
Specialty Generics Market by Product Type, Drug Delivery System, Molecule Type, Disease Indication, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Specialty Generics Market by Product Type, Drug Delivery System, Molecule Type, Disease Indication, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012051
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Specialty generics represent a dynamic segment within the pharmaceutical industry, offering crucial cost efficiencies and reliability for health systems seeking to balance access with therapeutic value. As manufacturers, payers, and providers adapt to changing regulatory environments and technological advancements, specialty generics are solidifying their role in diverse therapeutic markets.

Market Snapshot: Specialty Generics Market

The Specialty Generics Market grew from USD 93.56 billion in 2024 to USD 103.78 billion in 2025. It is expected to continue expanding at a CAGR of 10.83%, reaching USD 173.44 billion by 2030. This growth underscores increasing demand influenced by patent expiries, rising chronic disease prevalence, and greater acceptance of biosimilars and complex generics by global health systems.

Scope & Segmentation

  • Product Types: Biosimilars (including monoclonal antibodies and recombinant proteins) and small molecules (injectables such as pre-filled syringes and vials, liquid oral dosage forms, solid oral dosage forms).
  • Drug Delivery Systems: Inhalation therapies, injectables, oral medications, and topical formulations designed for targeted or systemic delivery.
  • Molecule Types: Biologics (focused on monoclonal antibodies, recombinant proteins) and chemical entities with established synthetic pathways.
  • Disease Indications: Autoimmune disorders, hormonal disorders, oncology, and other high-burden chronic conditions.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies, each presenting distinct engagement and supply chain approaches.
  • Regional Coverage: Americas (including United States states such as California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (comprising United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (covering China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Companies Profiled: Key industry leaders such as Sandoz International GmbH, Teva Pharmaceutical Industries Limited, Fresenius Kabi AG, Viatris Inc., Pfizer Inc., Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Limited, Baxter International Inc., Amneal Pharmaceuticals, Inc., and Apotex Inc. are analyzed for strategies and market position.

Key Takeaways

  • Patent losses among biologics and high-value small molecules are fueling the introduction of specialty generics, prompting competitive activity among both established and emerging players.
  • Regulatory authorities are streamlining biosimilar and generic approvals and have introduced stricter standards for demonstrating safety and comparability, which manufacturers must address through significant technical expertise.
  • Healthcare systems are increasingly adopting value-based and patient-centric contracting models, incentivizing manufacturers to invest in real-world evidence and enhanced patient support programs.
  • Technology adoption, especially in digital supply chain management and manufacturing process monitoring, is enabling greater transparency and flexibility, crucial for adapting to evolving trade policies and regulatory requirements.
  • Partnerships—whether with biotechnology innovators, contract manufacturers, or technology providers—are proving vital for companies aiming to broaden portfolios and accelerate speed to market.

Tariff Impact & Supply Chain Adaptation

The implementation of new United States tariffs in 2025 has challenged specialty generics producers to rethink sourcing strategies and strengthen vertical integration. Companies with adaptable, onshore manufacturing and diversified procurement relationships are better positioned to insulate margins, while negotiations with payers grow more complex due to cost pressures.

Methodology & Data Sources

This Specialty Generics Market analysis incorporated mixed-methods research, combining primary interviews with senior executives, regulatory consultants, and payers, alongside secondary sources such as filings, guidelines, and industry literature. Robust data triangulation and validation by internal experts support the reliability and actionable nature of these findings.

Why This Report Matters

  • Enables strategic planning by providing a detailed breakdown of market dynamics, segment opportunities, and regional trends.
  • Offers actionable insights on adapting supply chains, pricing, and engagement strategies in response to regulatory shifts and tariff changes.
  • Supports informed decision making for portfolio development, commercialization, and long-term risk mitigation in the specialty generics sector.

Conclusion

The specialty generics market is evolving in response to shifting regulations, technological innovation, and regional market forces. Companies that prioritize supply chain agility, differentiated partnerships, and segment-driven strategies will be best equipped for sustainable growth and competitive advantage.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Specialty Generics Market, by Product Type
8.1. Introduction
8.2. Biosimilar
8.2.1. Monoclonal Antibodies
8.2.2. Recombinant Proteins
8.3. Small Molecule
8.3.1. Injectables
8.3.1.1. Pre-Filled Syringes
8.3.1.2. Vials
8.3.2. Liquid Oral Dosage Forms
8.3.3. Solid Oral Dosage Forms
9. Specialty Generics Market, by Drug Delivery System
9.1. Introduction
9.2. Inhalation
9.3. Injectables
9.4. Oral
9.5. Topical
10. Specialty Generics Market, by Molecule Type
10.1. Introduction
10.2. Biologic
10.2.1. Monoclonal Antibodies
10.2.2. Recombinant Proteins
10.3. Chemical Entity
11. Specialty Generics Market, by Disease Indication
11.1. Introduction
11.2. Autoimmune
11.3. Hormonal Disorders
11.4. Oncology
12. Specialty Generics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Specialty Generics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Specialty Generics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Specialty Generics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Sandoz International GmbH
16.3.2. Teva Pharmaceutical Industries Limited
16.3.3. Fresenius Kabi AG
16.3.4. Viatris Inc.
16.3.5. Pfizer Inc.
16.3.6. Hikma Pharmaceuticals PLC
16.3.7. Dr. Reddy’s Laboratories Limited
16.3.8. Baxter International Inc.
16.3.9. Amneal Pharmaceuticals, Inc.
16.3.10. Apotex Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SPECIALTY GENERICS MARKET MULTI-CURRENCY
FIGURE 2. SPECIALTY GENERICS MARKET MULTI-LANGUAGE
FIGURE 3. SPECIALTY GENERICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SPECIALTY GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SPECIALTY GENERICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SPECIALTY GENERICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SPECIALTY GENERICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SPECIALTY GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY LIQUID ORAL DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SOLID ORAL DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY CHEMICAL ENTITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. CANADA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 60. CANADA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 61. CANADA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 62. CANADA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 63. CANADA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 65. CANADA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 66. CANADA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. MEXICO SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 69. MEXICO SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 71. MEXICO SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 72. MEXICO SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 74. MEXICO SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. GERMANY SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 114. GERMANY SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 115. GERMANY SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 116. GERMANY SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 117. GERMANY SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 118. GERMANY SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 119. GERMANY SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 120. GERMANY SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 121. GERMANY SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. FRANCE SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. FRANCE SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 124. FRANCE SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 125. FRANCE SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 126. FRANCE SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 127. FRANCE SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 128. FRANCE SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 129. FRANCE SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 130. FRANCE SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. ITALY SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. ITALY SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 142. ITALY SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 143. ITALY SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 144. ITALY SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 145. ITALY SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 146. ITALY SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 147. ITALY SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 148. ITALY SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. SPAIN SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. SPAIN SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 151. SPAIN SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 152. SPAIN SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 153. SPAIN SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 154. SPAIN SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 155. SPAIN SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 156. SPAIN SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 157. SPAIN SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. DENMARK SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. DENMARK SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 187. DENMARK SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 188. DENMARK SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 189. DENMARK SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 190. DENMARK SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 191. DENMARK SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 192. DENMARK SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 193. DENMARK SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. QATAR SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 204. QATAR SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 205. QATAR SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 206. QATAR SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 207. QATAR SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 208. QATAR SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 209. QATAR SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 210. QATAR SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 211. QATAR SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. FINLAND SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. FINLAND SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 214. FINLAND SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 215. FINLAND SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 216. FINLAND SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 217. FINLAND SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 218. FINLAND SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 219. FINLAND SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 220. FINLAND SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. EGYPT SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. EGYPT SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 241. EGYPT SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 242. EGYPT SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 243. EGYPT SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 244. EGYPT SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 245. EGYPT SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 246. EGYPT SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 247. EGYPT SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. TURKEY SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. TURKEY SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 250. TURKEY SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 251. TURKEY SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 252. TURKEY SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 253. TURKEY SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 254. TURKEY SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 255. TURKEY SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 256. TURKEY SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. NORWAY SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 267. NORWAY SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 268. NORWAY SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 269. NORWAY SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 270. NORWAY SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 271. NORWAY SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 272. NORWAY SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 273. NORWAY SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 274. NORWAY SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. POLAND SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. POLAND SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 277. POLAND SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 278. POLAND SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 279. POLAND SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 280. POLAND SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 281. POLAND SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 282. POLAND SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 283. POLAND SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 285. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 303. CHINA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. CHINA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 305. CHINA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 306. CHINA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 307. CHINA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 308. CHINA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 309. CHINA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 310. CHINA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 311. CHINA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. INDIA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 313. INDIA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 314. INDIA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 315. INDIA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 316. INDIA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 317. INDIA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 318. INDIA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 319. INDIA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 320. INDIA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. JAPAN SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 322. JAPAN SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 323. JAPAN SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 324. JAPAN SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 325. JAPAN SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 326. JAPAN SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 327. JAPAN SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 328. JAPAN SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 329. JAPAN SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 330. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 331. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 332. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 339. SOUTH KOREA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 340. SOUTH KOREA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 341. SOUTH KOREA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 342. SOUTH KOREA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 343. SOUTH KOREA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 344. SOUTH KOREA SPECI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Specialty Generics market report include:
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Limited
  • Fresenius Kabi AG
  • Viatris Inc.
  • Pfizer Inc.
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy’s Laboratories Limited
  • Baxter International Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 103.78 Billion
Forecasted Market Value ( USD ) by 2030 $ 173.44 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Buccal Drug Delivery Systems Market by Product Type, Drug Class, Application, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Buccal Drug Delivery Systems Market by Product Type, Drug Class, Application, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Drug Delivery System Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Drug Delivery System Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 86 Pages
  • Global
From
Novel Drug Delivery Systems Market by Route of Administration, Technology, Application, Product Type, End User - Global Forecast to 2030 - Product Image

Novel Drug Delivery Systems Market by Route of Administration, Technology, Application, Product Type, End User - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Electronic Drug Delivery Systems Market Report 2025 - Product Image

Electronic Drug Delivery Systems Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hydrogel-based Drug Delivery System Market Size, Share & Trends Analysis Report By Polymer Origin (Natural, Synthetic, Hybrid), By Delivery Route, By Region, And Segment Forecast, 2024 - 2030 - Product Image

Hydrogel-based Drug Delivery System Market Size, Share & Trends Analysis Report By Polymer Origin (Natural, Synthetic, Hybrid), By Delivery Route, By Region, And Segment Forecast, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.